News Releases August 30, 2023 Ventyx Biosciences to Participate in Two Upcoming Investor Conferences Read more August 10, 2023 Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress Read more August 3, 2023 Ventyx Biosciences to Report Second Quarter 2023 Financial Results on August 10, 2023 Read more August 2, 2023 Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference Read more June 14, 2023 Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor Read more June 7, 2023 Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis Read more May 31, 2023 Ventyx Biosciences to Participate in Two Upcoming Investor Conferences Read more May 11, 2023 Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress Read more May 4, 2023 Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023 Read more March 24, 2023 Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference Read more Current page 1 Page 2 Page 3 Page 4 Next page › Last page » Displaying 1 - 10 of 40
